Username

Password

Preview

Sign-in free and Explore the Exciting World of BiomedExperts:

Over 1.500.000 Profiles
More than 1.800 Organizations worldwide
State of the Art Network Visualizations

Manage your own Profile
Locate Experts in your Country/Region
Locate Experts in your 1. and 2. Level Network
Connect to Experts Worldwide

NetworkView

Philip Philip

This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles free of charge to researchers worldwide.

Research Profile (preview)

Procedures

Antineoplastic Combined Chemotherapy Protocols

Chemicals & Drugs

Disorders

Concepts & Ideas

Anatomy

Tumor Cell Line

Phenomena

Drug Synergism

Sign-in to see full Profile

Sign-in to see all Coauthors

Publications

TOP 3
Li Yiwei; VandenBoom Timothy G; Kong Dejuan; Wang Zhiwei; Ali Shadan; Philip Philip A; Sarkar Fazlul H
Up-regulation of miR-200 and let-7 by natural agents leads to the reversal of epithelial-to-mesenchymal transition in gemcitabine-resistant pancreatic cancer cells.
Ali Shadan; Al-Sukhun Sana; El-Rayes Bassel F; Sarkar Fazlul H; Heilbrun Lance K; Philip Philip A
Protein kinases C isozymes are differentially expressed in human breast carcinomas.
Gadgeel Shirish M; Ali Shadan; Philip Philip A; Wozniak Antoinette; Sarkar Fazlul H
Genistein enhances the effect of epidermal growth factor receptor tyrosine kinase inhibitors and inhibits nuclear factor kappa B in nonsmall cell lung cancer cell lines.

Sign-in to see all Publications

Sign in free and see...

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the visualized research activity
of experts around the globe

Sign-in to see more

Geonetwork of Philip Philip (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Sign-in to see more

All Publications

2009: Li Yiwei; VandenBoom Timothy G; Kong Dejuan; Wang Zhiwei; Ali Shadan; Philip Philip A; Sarkar Fazlul H
Up-regulation of miR-200 and let-7 by natural agents leads to the reversal of epithelial-to-mesenchymal transition in gemcitabine-resistant pancreatic cancer cells.
Cancer research 2009;69(16):6704-12.
2009: Ali Shadan; Al-Sukhun Sana; El-Rayes Bassel F; Sarkar Fazlul H; Heilbrun Lance K; Philip Philip A
Protein kinases C isozymes are differentially expressed in human breast carcinomas.
Life sciences 2009;84(21-22):766-71.
2009: Gadgeel Shirish M; Ali Shadan; Philip Philip A; Wozniak Antoinette; Sarkar Fazlul H
Genistein enhances the effect of epidermal growth factor receptor tyrosine kinase inhibitors and inhibits nuclear factor kappa B in nonsmall cell lung cancer cell lines.
Cancer 2009;115(10):2165-76.
2009: Ali Ashhar S; Ali Shadan; El-Rayes Bassel F; Philip Philip A; Sarkar Fazlul H
Exploitation of protein kinase C: a useful target for cancer therapy.
Cancer treatment reviews 2009;35(1):1-8.
2009: Philip Philip A
First- and second-line treatment of metastatic pancreatic adenocarcinoma: the conundrum continues.
Gastrointestinal cancer research : GCR 2009;3(1):37-9.
2008: Philip Philip A
Targeted therapies for pancreatic cancer.
Gastrointestinal cancer research : GCR 2008;2(4 Suppl):S16-9.
2008: Ali Shadan; Banerjee Sanjeev; Ahmad Aamir; El-Rayes Bassel F; Philip Philip A; Sarkar Fazlul H
Apoptosis-inducing effect of erlotinib is potentiated by 3,3'-diindolylmethane in vitro and in vivo using an orthotopic model of pancreatic cancer.
Molecular cancer therapeutics 2008;7(6):1708-19.
2008: Philip Philip A
Targeting angiogenesis in pancreatic cancer.
Lancet 2008;371(9630):2062-4.
2008: Louvet Christophe; Philip Philip A
Accomplishments in 2007 in the treatment of metastatic pancreatic cancer.
Gastrointestinal cancer research : GCR 2008;2(3 Suppl):S37-41.
2008: El-Rayes Bassel F; Ali Shadan; Philip Philip A; Sarkar Fazlul H
Protein kinase C: a target for therapy in pancreatic cancer.
Pancreas 2008;36(4):346-52.
2008: Vandenboom Ii Timothy G; Li Yiwei; Philip Philip A; Sarkar Fazlul H
MicroRNA and Cancer: Tiny Molecules with Major Implications.
Current genomics 2008;9(2):97-109.
2008: Small William; Berlin Jordan; Freedman Gary M; Lawrence Theodore; Talamonti Mark S; Mulcahy Mary F; Chakravarthy A Bapsi; Konski Andre A; Zalupski Mark M; Philip Philip A; Kinsella Timothy J; Merchant Nipun B; Hoffman John P; Benson Al B; Nicol Steven; Xu Rong M; Gill John F; McGinn Cornelius J
Full-dose gemcitabine with concurrent radiation therapy in patients with nonmetastatic pancreatic cancer: a multicenter phase II trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(6):942-7.
2008: El-Rayes Bassel F; Zalupski Mark M; Manza Stephanie G; Rusin Barbara; Ferris Ann Marie; Vaishampayan Ulka; Heilbrun Lance K; Venkatramanamoorthy Raghu; Shields Anthony F; Philip Philip A
Phase-II study of dose attenuated schedule of irinotecan, capecitabine, and celecoxib in advanced colorectal cancer.
Cancer chemotherapy and pharmacology 2008;61(2):283-9.
2008: Isacoff William H; Philip Philip A
Clinical management of long-term cancer survivors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(1):162-4.
2008: Philip Philip A
Improving treatment of pancreatic cancer.
The lancet oncology 2008;9(1):7-8.
2007: Gadgeel Shirish M; Ali Shadan; Philip Philip A; Ahmed Fakhara; Wozniak Antoinette; Sarkar Fazlul H
Response to dual blockade of epidermal growth factor receptor (EGFR) and cycloxygenase-2 in nonsmall cell lung cancer may be dependent on the EGFR mutational status of the tumor.
Cancer 2007;110(12):2775-84.
2007: Kachnic Lisa A; Ajani Jaffer A; Philip Philip A
Section II: Current Approaches to Treating Localized Gastrointestinal Cancers.
Gastrointestinal cancer research : GCR 2007;1(6 Suppl):S4-7.
2007: Goldberg Richard M; Marshall John L; Ajani Jaffer A; Philip Philip A; O'Reilly Eileen M; Venook Alan P
Section IV: Significance of Recent Study Results and Future Research Directions in Gastrointestinal Oncology.
Gastrointestinal cancer research : GCR 2007;1(6 Suppl):S13-6.
2007: Rahman K M Wahidur; Ali Shadan; Aboukameel Amro; Sarkar Sanila H; Wang Zhiwei; Philip Philip A; Sakr Wael A; Raz Avraham
Inactivation of NF-kappaB by 3,3'-diindolylmethane contributes to increased apoptosis induced by chemotherapeutic agent in breast cancer cells.
Molecular cancer therapeutics 2007;6(10):2757-65.
2007: Desai Sameer P; El-Rayes Basil F; Ben-Josef Edgar; Greenson Joel K; Knol James A; Huang Emina H; Griffith Kent A; Philip Philip A; McGinn Cornelius J; Zalupski Mark M
A phase II study of preoperative capecitabine and radiation therapy in patients with rectal cancer.
American journal of clinical oncology 2007;30(4):340-5.
2007: Schneider Bryan J; El-Rayes Basil; Muler Jeffery H; Philip Philip A; Kalemkerian Gregory P; Griffith Kent A; Zalupski Mark M
Phase II trial of carboplatin, gemcitabine, and capecitabine in patients with carcinoma of unknown primary site.
Cancer 2007;110(4):770-5.
2007: Ciuleanu T; Diculescu M; Hoepffner N M; Trojan J; Sailer V; Zalupski M; Herrmann T; Roth A; Chick J; Brock K; Albert D; Philip P A
A randomised phase II study of OSI-7904L versus 5-fluorouracil (FU)/leucovorin (LV) as first-line treatment in patients with advanced biliary cancers.
Investigational new drugs 2007;25(4):385-90.
2007: Isacoff William H; Bendetti Jacqueline K; Barstis John J; Jazieh Abdul-Rahman; Macdonald John S; Philip Philip A
Phase II trial of infusional fluorouracil, leucovorin, mitomycin, and dipyridamole in locally advanced unresectable pancreatic adenocarcinoma: SWOG S9700.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(13):1665-9.
2007: El-Rayes Basil F; Zalupski Mark; Shields Anthony F; Manza Stephanie G; LoRusso Patricia; Philip Philip A
A phase I study of gemcitabine and uracil-ftorfar (UFT)/leucovorin.
American journal of clinical oncology 2007;30(2):101-5.
2006: El-Rayes Basil F; Gadgeel Shirish; Shields Anthony F; Manza Stephanie; Lorusso Patricia; Philip Philip A
Phase I study of bryostatin 1 and gemcitabine.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(23):7059-62.
2006: El-Rayes Basil F; Ali Shadan; Ali Ifrah F; Philip Philip A; Abbruzzese James; Sarkar Fazlul H
Potentiation of the effect of erlotinib by genistein in pancreatic cancer: the role of Akt and nuclear factor-kappaB.
Cancer research 2006;66(21):10553-9.
2006: Thatai Lata Chandi; Vishnubhotla Priya; Biernat Laura; Flaherty Lawrence; LoRusso Patricia; Simon Michael; Stephens Deanna; Vereeke Kelly; Abrams Judith; Bouwman David; Philip Philip A
A phase II study of docetaxel, doxorubicin, and infusional 5-fluorouracil in the treatment of patients with locally advanced breast cancer.
American journal of clinical oncology 2006;29(5):484-9.
2006: Hochster Howard S; Haller Daniel G; de Gramont Aimery; Berlin Jordan D; Philip Philip A; Moore Malcolm J; Ajani Jaffer A
Consensus report of the international society of gastrointestinal oncology on therapeutic progress in advanced pancreatic cancer.
Cancer 2006;107(4):676-85.
2006: Philip Philip A; Mahoney Michelle R; Allmer Cristine; Thomas James; Pitot Henry C; Kim George; Donehower Ross C; Fitch Tom; Picus Joel; Erlichman Charles
Phase II study of erlotinib in patients with advanced biliary cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(19):3069-74.
2006: El-Rayes Basil F; Gadgeel Shirish; Parchment Ralph; Lorusso Patricia; Philip Philip A
A phase I study of flavopiridol and docetaxel.
Investigational new drugs 2006;24(4):305-10.
2006: Cote M L; Wenzlaff A S; Philip P A; Schwartz A G
Secondary cancers after a lung carcinoid primary: a population-based analysis.
Lung cancer (Amsterdam, Netherlands) 2006;52(3):273-9.
2006: Lu H; Wang J J; Chan K K; Philip P A
Stereoselectivity in metabolism of ifosfamide by CYP3A4 and CYP2B6.
Xenobiotica; the fate of foreign compounds in biological systems 2006;36(5):367-85.
2006: Talamonti Mark S; Small William; Mulcahy Mary F; Wayne Jeffrey D; Attaluri Vikram; Colletti Lisa M; Zalupski Mark M; Hoffman John P; Freedman Gary M; Kinsella Timothy J; Philip Philip A; McGinn Cornelius J
A multi-institutional phase II trial of preoperative full-dose gemcitabine and concurrent radiation for patients with potentially resectable pancreatic carcinoma.
Annals of surgical oncology 2006;13(2):150-8.
2005: Ali Shadan; El-Rayes Basil F; Sarkar Fazlul H; Philip Philip A
Simultaneous targeting of the epidermal growth factor receptor and cyclooxygenase-2 pathways for pancreatic cancer therapy.
Molecular cancer therapeutics 2005;4(12):1943-51.
2005: El-Rayes Basil F; Zalupski Mark M; Shields Anthony F; Ferris Ann Marie; Vaishampayan Ulka; Heilbrun Lance K; Venkatramanamoorthy Raghu; Adsay Volkan; Philip Philip A
A phase II study of celecoxib, gemcitabine, and cisplatin in advanced pancreatic cancer.
Investigational new drugs 2005;23(6):583-90.
2005: Banerjee Sanjeev; Zhang Yuxiang; Ali Shadan; Bhuiyan Mohammad; Wang Zhiwei; Chiao Paul J; Philip Philip A; Abbruzzese James; Sarkar Fazlul H
Molecular evidence for increased antitumor activity of gemcitabine by genistein in vitro and in vivo using an orthotopic model of pancreatic cancer.
Cancer research 2005;65(19):9064-72.
2005: Philip Philip A; Mahoney Michelle R; Allmer Cristine; Thomas James; Pitot Henry C; Kim George; Donehower Ross C; Fitch Tom; Picus Joel; Erlichman Charles
Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(27):6657-63.
2005: Li Yiwei; Ahmed Fakhara; Ali Shadan; Philip Philip A; Kucuk Omer; Sarkar Fazlul H
Inactivation of nuclear factor kappaB by soy isoflavone genistein contributes to increased apoptosis induced by chemotherapeutic agents in human cancer cells.
Cancer research 2005;65(15):6934-42.
2005: Philip Philip A
Experience with docetaxel in the treatment of gastric cancer.
Seminars in oncology 2005;32(2 Suppl 4):S24-38.
2005: El-Rayes Basil F; Shields Anthony F; Zalupski Mark; Heilbrun Lance K; Jain Vikash; Terry Damita; Ferris Ann Marie; Philip Philip A
A phase II study of carboplatin and paclitaxel in adenocarcinoma of unknown primary.
American journal of clinical oncology 2005;28(2):152-6.
2005: Ali Shadan; El-Rayes Basil F; Aranha Olivia; Sarkar Fazlul H; Philip Philip A
Sequence dependent potentiation of gemcitabine by flavopiridol in human breast cancer cells.
Breast cancer research and treatment 2005;90(1):25-31.
2005: El-Rayes Basil F; Ibrahim Dina; Shields Anthony F; LoRusso Patricia M; Zalupski Mark M; Philip Philip A
Phase I study of liposomal doxorubicin (Doxil) and cyclophosphamide in solid tumors.
Investigational new drugs 2005;23(1):57-62.
2004: El-Rayes Basil F; Ali Shadan; Sarkar Fazlul H; Philip Philip A
Cyclooxygenase-2-dependent and -independent effects of celecoxib in pancreatic cancer cell lines.
Molecular cancer therapeutics 2004;3(11):1421-6.
2004: Ali Shadan; El-Rayes Basil F; Heilbrun Lance K; Sarkar Fazlul H; Ensley John F; Kucuk Omar; Philip Philip A
Cytochrome p450 and glutathione transferase expression in squamous cell cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(13):4412-6.
2004: El-Rayes B F; Shields A; Zalupski M; Heilbrun L K; Jain V; Terry D; Ferris A; Philip P A
A phase II study of carboplatin and paclitaxel in esophageal cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2004;15(6):960-5.
2004: Ben-Josef Edgar; Shields Anthony F; Vaishampayan Ulka; Vaitkevicius Vainutis; El-Rayes Basil F; McDermott Patrick; Burmeister Jay; Bossenberger Todd; Philip Philip A
Intensity-modulated radiotherapy (IMRT) and concurrent capecitabine for pancreatic cancer.
International journal of radiation oncology, biology, physics 2004;59(2):454-9.
2004: Simon Michael S; Du Wei; Flaherty Lawrence; Philip Philip A; Lorusso Patricia; Miree Cheryl; Smith Daryn; Brown Diane R
Factors associated with breast cancer clinical trials participation and enrollment at a large academic medical center.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(11):2046-52.
2004: Li Yiwei; Ellis Kerrie-Lynn; Ali Shadan; El-Rayes Basil F; Nedeljkovic-Kurepa Ana; Kucuk Omer; Philip Philip A; Sarkar Fazlul H
Apoptosis-inducing effect of chemotherapeutic agents is potentiated by soy isoflavone genistein, a natural inhibitor of NF-kappaB in BxPC-3 pancreatic cancer cell line.
Pancreas 2004;28(4):e90-5.
2004: Puscheck Elizabeth; Philip Philip A; Jeyendran Rajasingam S
Male fertility preservation and cancer treatment.
Cancer treatment reviews 2004;30(2):173-80.
2003: Al-Sukhun Sana; Zalupski Mark M; Ben-Josef Edgar; Vaitkevicius Vainutis K; Philip Philip A; Soulen Renate; Weaver Donald; Adsay Volkan; Heilbrun Lance K; Levin Kenneth; Forman Jeffery D; Shields Anthony F
Chemoradiotherapy in the treatment of regional pancreatic carcinoma: a phase II study.
American journal of clinical oncology 2003;26(6):543-9.
2003: Ali Shadan; Aranha Olivia; Li Yiwei; Pettit George R; Sarkar Fazlul H; Philip Philip Agop
Sensitization of human breast cancer cells to gemcitabine by the protein kinase C modulator bryostatin 1.
Cancer chemotherapy and pharmacology 2003;52(3):235-46.
2003: Newman Lisa A; Pernick Nat L; Adsay Volkan; Carolin Kathryn A; Philip Philip A; Sipierski Susan; Bouwman David L; Kosir Mary A; White Michael; Visscher Daniel W;
Histopathologic evidence of tumor regression in the axillary lymph nodes of patients treated with preoperative chemotherapy correlates with breast cancer outcome.
Annals of surgical oncology 2003;10(7):734-9.
2003: El-Rayes B F; Zalupski M M; Shields A F; Vaishampayan U; Heilbrun L K; Jain V; Adsay V; Day J; Philip P A
Phase II study of gemcitabine, cisplatin, and infusional fluorouracil in advanced pancreatic cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(15):2920-5.
2003: El-Rayes Basil F; Philip Philip A
A review of systemic therapy for advanced pancreatic cancer.
Clinical advances in hematology & oncology : H&O 2003;1(7):430-4.
2003: El-Rayes Basil F; Ali Shadan; Heilbrun Lance K; Lababidi Samir; Bouwman David; Visscher David; Philip Philip A
Cytochrome p450 and glutathione transferase expression in human breast cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(5):1705-9.
2003: Gadgeel Shirish M; Shields Anthony F; Heilbrun Lance K; Labadidi Samir; Zalupski Mark; Chaplen Ruth; Philip Philip A
Phase II study of paclitaxel and carboplatin in patients with advanced gastric cancer.
American journal of clinical oncology 2003;26(1):37-41.
2003: Pernick Nat L; Sarkar Fazlul H; Philip Philip A; Arlauskas Patricia; Shields Anthony F; Vaitkevicius Vainutis K; Dugan Michael C; Adsay N Volkan
Clinicopathologic analysis of pancreatic adenocarcinoma in African Americans and Caucasians.
Pancreas 2003;26(1):28-32.
2003: Li Yiwei; Ali Shadan; Philip Philip A; Sarkar Fazlul H
Direct comparison of microarray gene expression profiles between non-amplification and a modified cDNA amplification procedure applicable for needle biopsy tissues.
Cancer detection and prevention 2003;27(5):405-11.
2003: el-Rayes B F; Shields A F; Vaitkevicius V; Philip P A
Developments in the systemic therapy of pancreatic cancer.
Cancer investigation 2003;21(1):73-86.
2002: El-Rayes Basil F; Berenji Kambeez; Schuman Paula; Philip Philip A;
Breast cancer in women with human immunodeficiency virus infection: implications for diagnosis and therapy.
Breast cancer research and treatment 2002;76(2):111-6.
2002: El-Rayes Basil F; Philip Philip A
Systemic therapy for advanced pancreatic cancer.
Expert review of anticancer therapy 2002;2(4):426-36.
2002: Philip Philip Agop
Gemcitabine and platinum combinations in pancreatic cancer.
Cancer 2002;95(4 Suppl):908-11.
2002: Vaishampayan U N; Ben-Josef E; Philip P A; Vaitkevicius V K; Du W; Levin K J; Shields A F
A single-institution experience with concurrent capecitabine and radiation therapy in gastrointestinal malignancies.
International journal of radiation oncology, biology, physics 2002;53(3):675-9.
2001: Adsay N V; El-Rayes B F; Philip P A
Pancreatic cancer: the evolving role of systemic therapy.
Expert opinion on pharmacotherapy 2001;2(12):1939-47.
2001: Mohammad R M; Adsay N V; Philip P A; Pettit G R; Vaitkevicius V K; Sarkar F H
Bryostatin 1 induces differentiation and potentiates the antitumor effect of Auristatin PE in a human pancreatic tumor (PANC-1) xenograft model.
Anti-cancer drugs 2001;12(9):735-40.
2001: Merati K; said Siadaty M; Andea A; Sarkar F; Ben-Josef E; Mohammad R; Philip P; Shields A F; Vaitkevicius V; Grignon D J; Adsay N V
Expression of inflammatory modulator COX-2 in pancreatic ductal adenocarcinoma and its relationship to pathologic and clinical parameters.
American journal of clinical oncology 2001;24(5):447-52.
2001: Philip P A; Zalupski M M; Vaitkevicius V K; Arlauskas P; Chaplen R; Heilbrun L K; Adsay V; Weaver D; Shields A F
Phase II study of gemcitabine and cisplatin in the treatment of patients with advanced pancreatic carcinoma.
Cancer 2001;92(3):569-77.
2001: Zonder J A; Shields A F; Zalupski M; Chaplen R; Heilbrun L K; Arlauskas P; Philip P A
A phase II trial of bryostatin 1 in the treatment of metastatic colorectal cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2001;7(1):38-42.
2000: Philip P A; Flaherty L E
Biochemotherapy for melanoma.
Current oncology reports 2000;2(4):314-21.
1999: O'Byrne K J; Philip P A; Propper D J; Braybrooke J P; Saunders M P; Bates N P; Taylor M A; Madigan D; Ganesan T S; Talbot D C; Harris A L
A phase II study of the modulation of 5-fluorouracil and folinic acid with high-dose infusional hydroxyurea in metastatic colorectal carcinoma.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1999;10(8):981-3.
1999: Philip P A; Ibrahim D; Zalupski M; Arlauskas P; Shields A
Gemcitabine and UFT plus oral calcium folinate: phase I study.
Oncology (Williston Park, N.Y.) 1999;13(7 Suppl 3):116-9.
1999: Philip P A; Rea D; Mitchell K; Carmichael J; Harris A L; Talbot D C
A pilot study of increasing dose intensity of epirubicin and ifosfamide in patients with small cell lung cancer by using recombinant granulocyte colony-stimulating factor.
Clinical oncology (Royal College of Radiologists (Great Britain)) 1999;11(2):84-9.
1999: Shields A F; Philip P A; LoRusso P M; Ferris A M; Zalupski M M
Phase II study of CI-958 in colorectal cancer.
Cancer chemotherapy and pharmacology 1999;43(2):162-4.
1999: Philip P A; Ali-Sadat S; Doehmer J; Kocarek T; Akhtar A; Lu H; Chan K K
Use of V79 cells with stably transfected cytochrome P450 cDNAs in studying the metabolism and effects of cytotoxic drugs.
Cancer chemotherapy and pharmacology 1999;43(1):59-67.
1998: Macaulay V M; O'Byrne K J; Green J A; Philip P A; McKinley L; LaCreta F P; Winograd B; Ganesan T S; Harris A L; Talbot D C
Phase I study of the mitomycin C analogue BMS-181174.
British journal of cancer 1998;77(11):2020-7.
1998: Philip P A
Interleukin-2 in the treatment of malignant melanoma.
Expert opinion on investigational drugs 1998;7(3):361-71.
1998: Zalupski M M; Shields A F; Philip P A; Kraut M; LoRusso P; Heilbrun L K; Vaitkevicius V
Evaluation of pyrazoloacridine in patients with advanced pancreatic carcinoma.
Investigational new drugs 1998;16(1):93-6.
1997: Philip P A; Zalupski M M; Gadgeel S; Hussain M; Shields A
A phase II study of carboplatin and paclitaxel in the treatment of patients with advanced esophageal and gastric cancer.
Seminars in oncology 1997;24(6 Suppl 19):S19-86-S19-88.
1997: Philip P A; Flaherty L
Treatment of malignant melanoma with interleukin-2.
Seminars in oncology 1997;24(1 Suppl 4):S32-8.
1997: Zalupski M M; Philip P A; LoRusso P; Shields A F
Phase II study of pyrazoloacridine in patients with advanced colorectal carcinoma.
Cancer chemotherapy and pharmacology 1997;40(3):225-7.
1996: Philip P A; Souliotis V L; Harris A L; Salisbury A; Tates A D; Mitchell K; van Delft J H; Ganesan T S; Kyrtopoulos S A
Methyl DNA adducts, DNA repair, and hypoxanthine-guanine phosphoribosyl transferase mutations in peripheral white blood cells from patients with malignant melanoma treated with dacarbazine and hydroxyurea.
Clinical cancer research : an official journal of the American Association for Cancer Research 1996;2(2):303-10.
1995: Philip P A; Harris A L
Potential for protein kinase C inhibitors in cancer therapy.
Cancer treatment and research 1995;78():3-27.
1995: Carmichael J; Philip P A; Forfar C; Harris A L
An open study to assess the safety, tolerance and pharmacokinetics of an intravenous infusion of granisetron given at 3 mg over 30 s in patients receiving chemotherapy for malignant disease.
Cancer chemotherapy and pharmacology 1995;37(1-2):134-8.
1994: Philip P A; Ajani J A
Has combined modality therapy improved the outlook in carcinoma of the esophagus?
Oncology (Williston Park, N.Y.) 1994;8(9):37-42; discussion 44-5, 50-2, 61.
1994: Philip P A; Kaklamanis L; Ryley N; Stratford I; Wolf R; Harris A; Carmichael J
Expression of xenobiotic-metabolizing enzymes by primary and secondary hepatic tumors in man.
International journal of radiation oncology, biology, physics 1994;29(2):277-83.
1994: Philip P A; Carmichael J; Tonkin K; Ganesan T A; Harris A L
A phase II study of high-dose hydroxyurea and dacarbazine (DTIC) in the treatment of metastatic malignant melanoma.
European journal of cancer (Oxford, England : 1990) 1994;30A(7):1027-9.
1993: Philip P A; Thompson C H; Carmichael J; Rea D; Mitchell K; Taylor D J; Stuart N S; Dennis I; Rajagopalan B; Ganesan T
A phase I study of the left-shifting agent BW12C79 plus mitomycin C and the effect on the skeletal muscle metabolism using 31P magnetic resonance spectroscopy.
Cancer research 1993;53(23):5649-53.
1993: Philip P A; Rea D; Thavasu P; Carmichael J; Stuart N S; Rockett H; Talbot D C; Ganesan T; Pettit G R; Balkwill F
Phase I study of bryostatin 1: assessment of interleukin 6 and tumor necrosis factor alpha induction in vivo. The Cancer Research Campaign Phase I Committee.
Journal of the National Cancer Institute 1993;85(22):1812-8.
1993: Philip P A; Kaklamanis L; Carmichael J; Tonkin K; Morrison H; Gatter K; Harris A L
The influence of high dose hydroxyurea on the incorporation of 5-iodo-2-deoxyuridine (IUdR) by human bone marrow and tumour cells in vivo.
British journal of cancer 1993;67(4):644-9.
1993: Philip P A; Carmichael J; Tonkin K; Buamah P K; Britton J; Dowsett M; Harris A L
Hormonal treatment of pancreatic carcinoma: a phase II study of LHRH agonist goserelin plus hydrocortisone.
British journal of cancer 1993;67(2):379-82.
1992: Stuart N S; Philip P; Harris A L; Tonkin K; Houlbrook S; Kirk J; Lien E A; Carmichael J
High-dose tamoxifen as an enhancer of etoposide cytotoxicity. Clinical effects and in vitro assessment in p-glycoprotein expressing cell lines.
British journal of cancer 1992;66(5):833-9.
1992: Philip P A; Joel S; Monkman S C; Dolega-Ossowski E; Tonkin K; Carmichael J; Idle J R; Harris A L
A phase I study on the reversal of multidrug resistance (MDR) in vivo: nifedipine plus etoposide.
British journal of cancer 1992;65(2):267-70.
1992: Rustin G J; Stratford M R; Lamont A; Bleehen N; Philip P A; Howells N; Watfa R R; Slack J A
Phase I study of intravenous 4-hydroxyanisole.
European journal of cancer (Oxford, England : 1990) 1992;28A(8-9):1362-4.
1991: Philip P A; Rustin G J; Ledermann J A; Begent R H; Newlands E S; Bagshawe K D
Weekly etoposide, methotrexate and actinomycin D, alternating with cyclophosphamide plus vincristine (EMA/CO): a phase II study in advanced gastric carcinoma.
Clinical oncology (Royal College of Radiologists (Great Britain)) 1991;3(4):214-6.
1991: Philip P A; Carmichael J; Harris A L
Convulsions and transient cortical blindness after cisplatin.
BMJ (Clinical research ed.) 1991;302(6773):416.
1991: Philip P A; Bagshawe K D; Searle F; Green A J; Begent R H; Newlands E S; Rustin G J; Adam T
In vivo uptake of 131I-5-iodo-2-deoxyuridine by malignant tumours in man.
British journal of cancer 1991;63(1):134-5.
1989: Philip P A; James C A; Rogers H J
The influence of cimetidine on debrisoquine 4-hydroxylation in extensive metabolizers.
European journal of clinical pharmacology 1989;36(3):319-21.
1989: Philip P A; Harper P G; Rogers H J
Effect of cancer chemotherapy on dapsone N-acetylation in man.
Cancer chemotherapy and pharmacology 1989;23(6):395-6.
1988: Hitchins R N; Philip P A; Wignall B; Newlands E S; Begent R H; Rustin G J; Bagshawe K D
Bone disease in testicular and extragonadal germ cell tumours.
British journal of cancer 1988;58(6):793-6.
1988: Philip P A; Fitzgerald D L; Cartwright R A; Peake M D; Rogers H J
Polymorphic N-acetylation capacity in lung cancer.
Carcinogenesis 1988;9(3):491-3.
1988: Philip P A; Lewis L D; James C A; Rogers H J
Ifosfamide plasma clearance in relation to polymorphic debrisoquine oxidation.
Cancer chemotherapy and pharmacology 1988;22(4):321-4.
1987: Philip P A; James C A; Rogers H J
Determination of debrisoquine metabolic ratio from hourly urine collections in healthy volunteers.
British journal of clinical pharmacology 1987;24(6):827-9.
1987: Philip P A; Rogers H J; Millis R R; Rubens R D; Cartwright R A
Acetylator status and its relationship to breast cancer and other diseases of the breast.
European journal of cancer & clinical oncology 1987;23(11):1701-6.
1987: Ledermann J A; Crawford S M; Philip P A; Bagshawe K D
Curable metastatic cancer in young women.
British medical journal (Clinical research ed.) 1987;295(6595):432-3.
1987: Philip P A; Gayed S L; Rogers H J; Crome P
Influence of age, sex and body weight on the dapsone acetylation phenotype.
British journal of clinical pharmacology 1987;23(6):709-13.
1987: Philip P A; Rogers H J; Harper P G
Acetylation and oxidation phenotypes in malignant lymphoma.
Cancer chemotherapy and pharmacology 1987;20(3):235-8.
1984: Cartwright R A; Philip P A; Rogers H J; Glashan R W
Genetically determined debrisoquine oxidation capacity in bladder cancer.
Carcinogenesis 1984;5(9):1191-2.
1984: Philip P A; Roberts M S; Rogers H J
A rapid method for determination of acetylation phenotype using dapsone.
British journal of clinical pharmacology 1984;17(4):465-9.

Sign-in to see more

Sign-in free and Explore the Exciting World of BiomedExperts:

NetworkView

Philip Philip

Research Profile (preview)

Procedures

Chemicals & Drugs

Disorders

Concepts & Ideas

Anatomy

Phenomena

Network (preview)

Publications

Sign in free and see...

Visualized networks:

GeoTargeted Searches:

Research Profiles:

Geonetwork of Philip Philip (preview)

All Publications